Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial

Inflammopharmacology

Volumn 25, Issue 1, 2017, Pages 25-31

  Panahi, Yunes ^a   Khalili, Nahid ^a   Sahebi, Ebrahim ^b   Namazi, Soha ^b   Karimian, Maryam Saberi ^c   Majeed, Muhammed ^d   Sahebkar, Amirhossein ^c  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Sabinsa Inc   (United States)

Author keywords

Curcumin; Diabetes mellitus; Malondialdehyde; Oxidative stress; Superoxide dismutase; Total antioxidant capacity

Indexed keywords

CURCUMINOID; INSULIN; MALONALDEHYDE; PIPERINE; POLYPHENOL DERIVATIVE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; ANTIOXIDANT; CURCUMIN; GLUCOSE BLOOD LEVEL;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CURCUMA; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENT; DRUG EFFECTS; FOLLOW UP; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; PHYSIOLOGY; TREATMENT OUTCOME;

ADULT; ANTIOXIDANTS; BLOOD GLUCOSE; CURCUMA; CURCUMIN; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; TREATMENT OUTCOME;

EID: 85001740497     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-016-0301-4     Document Type: Article

References (63)

1. Amin F, Bano B (2012) Nitric oxide induced damage and preventive effect of curcumin and quercetin on buffalo brain cystatin Current. Proteomics 9:9–17
2. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4:807–818. doi:10.1021/mp700113r
3. Bajaj S, Khan A (2012) Antioxidants and diabetes. Indian J Endocrinol Metab 16:S267–S271. doi:10.4103/2230-8210.104057
4. Baum L, Ng A (2004) Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer’s disease animal models. J Alzheimer’s Dis 6:367–377
5. Biswas J, Sinha D, Mukherjee S, Roy S, Siddiqi M, Roy M (2010) Curcumin protects DNA damage in a chronically arsenic-exposed population of West Bengal. Hum Exp Toxicol 29:513–524. doi:10.1177/0960327109359020
6. Boaz M et al (2000) Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 356:1213–1218
7. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820
8. Ceriello A, Testa R (2009) Antioxidant anti-inflammatory treatment in type 2 diabetes. Diabetes care 32(Suppl 2):S232–S236. doi:10.2337/dc09-S316
9. Chait A, Bornfeldt KE (2009) Diabetes and atherosclerosis: is there a role for hyperglycemia? J Lipid Res 50:S335–S339
10. Derosa G, Maffioli P, Simental-Mendia LE, Bo S, Sahebkar A (2016) Effect of curcumin on circulating interleukin-6 concentrations: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 111:394–404. doi:10.1016/j.phrs.2016.07.004
11. DiSilvestro RA, Joseph E, Zhao S, Bomser J (2012a) Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J 11:1
12. DiSilvestro RA, Joseph E, Zhao S, Bomser J (2012b) Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J 11:79. doi:10.1186/1475-2891-11-79
13. Esmaily H, Sahebkar A, Iranshahi M, Ganjali S, Mohammadi A, Ferns G, Ghayour-Mobarhan M (2015) An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial Chinese journal of integrative medicine 21:332–338. doi:10.1007/s11655-015-2160-z
14. Ghandadi M, Sahebkar A (2016) Curcumin: an effective inhibitor of interleukin-6. Curr Pharm Des. doi:10.2174/1381612822666161006151605
15. Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107:1058–1070. doi:10.1161/CIRCRESAHA.110.223545
16. Hogan P, Dall T, Nikolov P (2003) Economic costs of diabetes in the US in 2002. Diabetes Care 26:917
17. Huang Y, Cai X, Chen P, Mai W, Tang H, Huang Y, Hu Y (2014) Associations of prediabetes with all-cause and cardiovascular mortality: a meta-analysis. Ann Med 46:684–692
18. Johansen JS, Harris AK, Rychly DJ, Ergul A (2005) Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 4:5. doi:10.1186/1475-2840-4-5
19. Karimian MS, Pirro M, Majeed M, Sahebkar A (2016) Curcumin as a natural regulator of monocyte chemoattractant protein-1. Cytokine Growth Factor Rev. doi:10.1016/j.cytogfr.2016.10.001
20. Kasi PD et al (2016) Molecular targets of curcumin for cancer therapy: an updated review. Tumour Biol J Int Soc Oncodev Biol Med. doi:10.1007/s13277-016-5183-y
21. Khonche A et al (2016) Adjunctive therapy with curcumin for peptic ulcer: a randomized controlled trial. Drug Res 66:444–448. doi:10.1055/s-0042-109394
22. Lonn E et al (2001) Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103:919–925
23. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC (2006) Multiple biological activities of curcumin: a short review. Life Sci 78:2081–2087
24. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A (1993) A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Lond) 84:407–412
25. Mirzaei H et al (2016) Curcumin: a new candidate for melanoma therapy? Int J Cancer 139:1683–1695. doi:10.1002/ijc.30224
26. Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, Ghayour-Mobarhan M, Ferns GA (2013) Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. PTR 27:374–379. doi:10.1002/ptr.4715
27. Momtazi AA, Sahebkar A (2016) Difluorinated curcumin: a promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile. Curr Pharm Des 22:4386–4397
28. Momtazi AA, Derosa G, Maffioli P, Banach M, Sahebkar A (2016a) Role of microRNAs in the therapeutic effects of curcumin in non-cancer diseases. Mol Diagn Ther 20:335–345. doi:10.1007/s40291-016-0202-7
29. Momtazi AA, Shahabipour F, Khatibi S, Johnston TP, Pirro M, Sahebkar A (2016b) Curcumin as a MicroRNA regulator in cancer: a review. Rev Physiol Biochem Pharmacol 171:1–38. doi:10.1007/112_2016_3
30. Montonen J, Knekt P, Jarvinen R, Reunanen A (2004) Dietary antioxidant intake and risk of type 2 diabetes. Diabetes Care 27:362–366
31. Na LX, Yan BL, Jiang S, Cui HL, Li Y, Sun CH (2014) Curcuminoids target decreasing serum adipocyte-fatty acid binding protein levels in their glucose-lowering effect in patients with type 2 diabetes. BES 27:902–906. doi:10.3967/bes2014.127
32. Palanisamy U, Manaharan T, Teng LL, Radhakrishnan AK, Subramaniam T, Masilamani T (2011) Rambutan rind in the management of hyperglycemia. Food Res Int 44:2278–2282
33. Panahi Y, Sahebkar A, Amiri M, Davoudi SM, Beiraghdar F, Hoseininejad SL, Kolivand M (2012a) Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br J Nutr 108:1272–1279. doi:10.1017/S0007114511006544
34. Panahi Y, Sahebkar A, Parvin S, Saadat A (2012b) A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 49:580–588. doi:10.1258/acb.2012.012040
35. Panahi Y, Khalili N, Hosseini MS, Abbasinazari M, Sahebkar A (2014a) Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med 22:851–857. doi:10.1016/j.ctim.2014.07.006
36. Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A (2014b) Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. PTR 28:1625–1631. doi:10.1002/ptr.5174
37. Panahi Y, Badeli R, Karami GR, Sahebkar A (2015a) Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. PTR 29:17–21. doi:10.1002/ptr.5211
38. Panahi Y, Ghanei M, Bashiri S, Hajihashemi A, Sahebkar A (2015b) Short-term curcuminoid supplementation for chronic pulmonary complications due to sulfur mustard intoxication: positive results of a randomized double-blind placebo-controlled trial. Drug Res 65:567–573. doi:10.1055/s-0034-1389986
39. Panahi Y, Hosseini MS, Khalili N, Naimi E, Majeed M, Sahebkar A (2015c) Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: a randomized controlled trial and an updated meta-analysis. Clin Nutr 34:1101–1108. doi:10.1016/j.clnu.2014.12.019
40. Panahi Y, Alishiri GH, Parvin S, Sahebkar A (2016a) Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: results of a randomized controlled trial. J Diet Suppl 13:209–220. doi:10.3109/19390211.2015.1008611
41. Panahi Y, Ghanei M, Hajhashemi A, Sahebkar A (2016b) Effects of curcuminoids-piperine combination on systemic oxidative stress, clinical symptoms and quality of life in subjects with chronic pulmonary complications due to sulfur mustard: a randomized controlled trial. J Diet Suppl 13:93–105. doi:10.3109/19390211.2014.952865
42. Panahi Y, Hosseini MS, Khalili N, Naimi E, Simental-Mendia LE, Majeed M, Sahebkar A (2016c) Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: a post hoc analysis of a randomized controlled trial. Biomed Pharmacother Biomedecine Pharmacotherapie 82:578–582. doi:10.1016/j.biopha.2016.05.037
43. Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendia LE, Sahebkar A (2016d) Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial. J Cardiovasc Pharmacol 68:223–229. doi:10.1097/FJC.0000000000000406
44. Piper JT, Singhal SS, Salameh MS, Torman RT, Awasthi YC, Awasthi S (1998) Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. Int J Biochem Cell Biol 30:445–456
45. Poitout V, Robertson RP (2008) Glucolipotoxicity: fuel excess and β-cell dysfunction. Endocr Rev 29:351–366
46. Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, Sahebkar A (2016) Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled. PTR 30:1540–1548. doi:10.1002/ptr.5659
47. Rother KI (2007) Diabetes treatment—bridging the divide. N Engl J Med 356:1499
48. Ruby A, Kuttan G, Babu KD, Rajasekharan K, Kuttan R (1995) Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 94:79–83
49. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26:3264–3272
50. Sahebkar A (2010) Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril 94:e75–e76; author reply e77. doi:10.1016/j.fertnstert.2010.07.1071
51. Sahebkar A (2013) Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? BioFactors 39:197–208. doi:10.1002/biof.1062
52. Sahebkar A (2014a) Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. PTR 28:633–642. doi:10.1002/ptr.5045
53. Sahebkar A (2014b) Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol 11:123. doi:10.1038/nrcardio.2013.140-c1
54. Sahebkar A, Henrotin Y (2016) Analgesic efficacy and safety of curcuminoids in clinical practice: a systematic review and meta-analysis of randomized controlled trials. Pain Med 17:1192–1202. doi:10.1093/pm/pnv024
55. Sahebkar A et al (2013) Curcuminoids modulate pro-oxidant–antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 27:1883–1888
56. Sahebkar A, Serban MC, Ursoniu S, Banach M (2015) Effect of curcuminoids on oxidative stress: a systematic review and meta-analysis of randomized controlled trials. J Funct Foods 18:898–909. doi:10.1016/j.jff.2015.01.005
57. Sahebkar A, Cicero AF, Simental-Mendia LE, Aggarwal BB, Gupta SC (2016) Curcumin downregulates human tumor necrosis factor-alpha levels: a systematic review and meta-analysis ofrandomized controlled trials. Pharmacol Res 107:234–242. doi:10.1016/j.phrs.2016.03.026
58. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS (1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64:353–356. doi:10.1055/s-2006-957450
59. Standl E, Müller M, Schnell O (2009) The impact of glucose-lowering therapy on cardiovascular outcomes. Best Pract Res Clin Endocrinol Metabol 23:401–411
60. Uchegbu NN, Ishiwu CN (2016) Germinated Pigeon Pea (Cajanus cajan): a novel diet for lowering oxidative stress and hyperglycemia. Food Sci Nutr
61. Vikramadithyan RK et al (2005) Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Investig 115:2434–2443
62. Zabihi NA, Pirro M, Johnston TP, Sahebkar A (2016) Is there a role for curcumin supplementation in the treatment of non-alcoholic fatty liver disease? The data suggest yes. Curr Pharm Des. doi:10.2174/1381612822666161010115235
63. Zhou H, Beevers CS, Huang S (2011) The targets of curcumin. Curr Drug Targ 12:332–347